Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
| ▸ | CCR4 | P51679 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18341971 | 0.75 | KDR (0.40) | AURKAAURKBKDREPHB4 | |
| SCHEMBL4764241 | 0.75 | KDR (0.40) | AURKAAURKBKDREPHB4 | |
| SCHEMBL31227729 | 0.72 | CA1 (0.35) | — | |
| SCHEMBL29503401 | 0.72 | KDR (0.57) | HIPK2AURKAAURKBKDREPHB4 | |
| SCHEMBL868356 | 0.72 | KDR (0.57) | HIPK2AURKAAURKBKDREPHB4 | |
| SCHEMBL29503516 | 0.72 | KDR (0.41) | HIPK2AURKAAURKBKDRSMN1; SMN2 | |
| SCHEMBL379508 | 0.72 | KDR (0.41) | HIPK2AURKAAURKBKDRSMN1; SMN2 | |
| SCHEMBL30958677 | 0.72 | KDR (0.38) | AURKAAURKBKDRSMN1; SMN2EPHB4 | |
| SCHEMBL17176672 | 0.72 | KDR (0.38) | AURKAAURKBKDRSMN1; SMN2EPHB4 | |
| SCHEMBL3475483 | 0.69 | HPGD (0.42) | CSNK2A1HIPK2LRRK2AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45173-E1 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| EP-2445903-B1 | 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | CSNK2A1 3209/4885HIPK2 4404/4885LRRK2 4603/4885 |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | CYP17A1, CYP21A2, CYP4A22 | CSNK2A1 3209/4885HIPK2 4404/4885LRRK2 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.